Lu AF28996 for Parkinson's Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Parkinson's DiseaseLu AF28996 - Drug
Eligibility
45 - 75
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to investigate the safety of Lu AF28996, how well it is tolerated and what the body does to the drug in participants with Parkinson's disease.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

6 Primary · 0 Secondary · Reporting Duration: 0 (predose) to 24 hours postdose on Day 1 to Day 62

Day 39
AUC(0-24h) of Lu AF28996
AUC(last) of Lu AF28996
CL/F of Lu AF28996
Cmax of Lu AF28996
Day 62
Amount of Lu AF28996, Lu AF28995, Lu AF29308, and Lu AF29309 Excreted in Urine
Day 62
Number of Participants with Treatment-emergent Adverse Events

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Lu AF28996
1 of 1

Experimental Treatment

37 Total Participants · 1 Treatment Group

Primary Treatment: Lu AF28996 · No Placebo Group · Phase 1

Lu AF28996
Drug
Experimental Group · 1 Intervention: Lu AF28996 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 0 (predose) to 24 hours postdose on day 1 to day 62

Who is running the clinical trial?

H. Lundbeck A/SLead Sponsor
317 Previous Clinical Trials
76,642 Total Patients Enrolled
Email contact via H. Lundbeck A/SStudy DirectorLundbeckClinicalTrials@Lundbeck.com
184 Previous Clinical Trials
57,951 Total Patients Enrolled

Eligibility Criteria

Age 45 - 75 · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: